Status:

TERMINATED

Impella CP With VA ECMO for Cardiogenic Shock

Lead Sponsor:

University of Pennsylvania

Conditions:

Cardiogenic Shock

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is indicated as a haemodynamic rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic shock. It has been...

Eligibility Criteria

Inclusion

  • Cardiogenic shock: Including refractory to conventional therapy, including systolic blood pressure \< 90mm Hg, Cardiac Index \< 1.8 or a cardiac index \< 2.0 on moderate to high doses of inotropes and vasopressors for greater than 30 mins, or systemic signs of tissue hypoxia.
  • Post-acute myocardial infarction cardiogenic shock: excluding mechanical complications requiring surgical intervention after extracorpeal membrane oxygenator (ECMO) such as post-ischaemic ventricular septal defect (VSD).
  • Drug overdose-induced cardiogenic shock.
  • Early graft failure: post orthotropic heart transplantation cardiogenic shock, excluding immediate intra-operative failure.
  • Acute on chronic cardiomyopathy with progressive shock and decompensation unresponsive to medical therapies.

Exclusion

  • Recent Significant Pulmonary Embolus
  • Moderate to severe aortic valve insufficiency (AI)
  • Ongoing significant sepsis
  • Severe pulmonary hypertension \& shock
  • Hypothermia
  • Post-cardiotomy cardiogenic shock
  • Continuous cardiopulmonary resuscitation (CPR) \>20-30 minutes, except if neurological status is satisfactory
  • Transfer from outside hospital on VA ECMO or with history of CPR
  • Listed for cardiopulmonary transplantation or being evaluated for cardiopulmonary transplantation or permanent mechanical circulatory support
  • Known or suspected chronic heart failure with echocardiogram documenting left ventricular diastolic diameter \>6.5cm
  • Known or suspected chronic heart failure with echocardiogram documenting left ventricular ejection fraction \< 25%
  • Mechanical aortic valve replacement
  • Presence of left ventricular thrombus
  • Pre-existing Impella 2.5, CP, 3.5 or 5.0
  • Cardiogenic shock due to primary respiratory failure
  • Mechanical complications requiring surgical intervention after ECMO such as post-ischaemic VSD.
  • Severe liver failure
  • Active malignancy
  • Acute aortic dissection
  • Intracranial hemorrhage
  • Neurological injury including recent cerebrovascular accident or suspected severe neurologic injury

Key Trial Info

Start Date :

March 19 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2023

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT03431467

Start Date

March 19 2018

End Date

September 1 2023

Last Update

November 19 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital of The University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104